Probiota Pioneers 2023: Deadline extension for entrepreneurial microbiome players

By Stephen Daniells

- Last updated on GMT

Deadline extended for Probiota Pioneers applications

Related tags Probiota americas Probiota Pioneers Unmetered Prebiotics microbiome Probiotics start-ups

The deadline for submitting entries for the 2023 Probiota Pioneers (microbiome focused start-ups) has been extended until April 14, 2023

Probiota Pioneers

NutraIngredients-USA is on the lookout for entrepreneurial consumer-facing, science- or technology-based start-ups to join our Probiota Pioneers session and present their company in Chicago!

There has never been a better time to launch a start-up in this field. As major universities look to spin-out and license key discoveries, global food and pharma businesses open up venture funds and external innovation programs and incubators to draw innovative entrepreneurs into their orbit – there are rich pickings for probiotic, prebiotic and microbiome pioneers in search of money, experience and a global platform for their ideas.

But how can you win in a competitive environment?

NutraIngredients-USA​ is seeking science- or technology-based entrepreneurial start-ups to join our Probiota Pioneers​ session and pitch their company and ideas to a room full of experts.

If selected as a Probiota Pioneer by our editorial panel you will receive:

-          A place on the Probiota Americas program as part of the Probiota Pioneers session to present your business

-          Access to the full program including all presentations and networking session – your chance to connect with some of the biggest names in pre and probiotics and the microbiome

-          Coverage in NutraIngredients-USA including preview articles and your opportunity to appear in multimedia coverage of the event.

For more information and to apply to Probiota Pioneers, please click HERE​.

Related news

Related products

show more

Redefine resilience with IMMUSE

Redefine resilience with IMMUSE

Content provided by Kyowa Hakko (US) | 02-May-2024 | White Paper

IMMUSETM is a universal postbiotic — the first of its kind to activate pDC cells for year-round immune support.

NAD+ Booster NMNH Proved for Safety and Efficacy

NAD+ Booster NMNH Proved for Safety and Efficacy

Content provided by Effepharm Ltd | 02-May-2024 | Product Brochure

NMNH, short for Reduced Beta-Nicotinamide Mononucleotide, refers to the reduced form of NMN. Preclinical studies show that NMNH demonstrates a remarkable...

Related suppliers

Follow us

Products

View more

Webinars